Endothelial cell loss after cataract phacoemulsification with Healon5 vs. I-Vise Phaco

Endothelial cell loss after cataract phacoemulsification with Healon S vs I-Vise Phaco.

Article specifications

This clinical trial was published in 2003 in Canadian journal of ophthalmology (IF 2016:1.543) by Canadian ophthalmologists. In this study the efficacy of 2 different OVDs, Healon5 (2.3% sodium hyaluronate) and I-Vise Phaco (2.5% sodium hyaluronate) was compared. In this article 96 patients scheduled to undergo cataract surgery assigned to receive I-Vise Phaco. This group was compared with 112 patients who had received Healon5 in a previous study by the author. The technique used to remove the cataract with phacoemulsification and insertion of an intraocular lens was the same in the two groups. Endothelial cell count and corneal thickness were measured preoperatively and 3 and 8 weeks postoperatively with a Konan noncontact specular microscope.

Results

In conclusion, Healon5 (2.3% sodium hyaluronate) and I-Vise Phaco (2.5% sodium hyaluronate) function similarly in facilitating cataract phacoemulsification and protecting corneal endothelial cells.